EARNINGS ARE COMING AND THE WORD IS. THEY WILL SHOW REVENUE FOR THE 1ST TIME SINCE THEY STARTED. THIS STOCK IS 47% SHORTED.
Did you know that just with the two therapies that have been approved, sickle cell disease and the other one related to cancer and T cells being overactive crisper therapeutics has an intrinsic value of $1075 per share. Just do the calculation. 70,000,000 afflicted with sickle cell disease, 5 million new afflicted people per year, and the T cell hyperactive condition on cancer patients flick 7% of all cancer patients. And you know that cancer will be the ultimate killer when you get old. That means that sickle cell therapy is pricing a 2,600,000 per treatment and the sickle cell hyperactive and cancer patients costs $1 million per treatment. I'll leave you with that thought. And by the way, if you think that Pharma will not go for this, you're wrong the payment upfront is much bigger than the payment overtime. And a chronic treatment for a patient afflicted with any of this diseases after you do the NPV net pressing value you realize that Chris therapy it's much better. Not only this, but the government has an incentive to actually cover part of the insurance cost of this therapies so they can integrate patients afflicted into the productive, workforce and generate income from tax revenue. This is why I believe that Chris therapeutics will be licensing very successfully. This therapies to Pharma far and wide, so the only bottleneck was insurance so the government will pick up the insurance that's for sure because it makes sense from a mathematical perspective.
Did you know that just with the two therapies that have been approved, sickle cell disease and the other one related to cancer and T cells being overactive crisper therapeutics has an intrinsic value of $1075 per share. Just do the calculation. 70,000,000 afflicted with sickle cell disease, 5 million new afflicted people per year, and the T cell hyperactive condition on cancer patients flick 7% of all cancer patients. And you know that cancer will be the ultimate killer when you get old. That means that sickle cell therapy is pricing a 2,600,000 per treatment and the sickle cell hyperactive and cancer patients costs $1 million per treatment. I'll leave you with that thought. And by the way, if you think that Pharma will not go for this, you're wrong the payment upfront is much bigger than the payment overtime. And a chronic treatment for a patient afflicted with any of this diseases after you do the NPV net pressing value you realize that Chris therapy it's much better. Not only this, but the government has an incentive to actually cover part of the insurance cost of this therapies so they can integrate patients afflicted into the productive, workforce and generate income from tax revenue. This is why I believe that Chris therapeutics will be licensing very successfully. This therapies to Pharma far and wide, so the only bottleneck was insurance so the government will pick up the insurance that's for sure because it makes sense from a mathematical perspective.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。